Navigation Links
Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
Date:5/17/2011

an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010, our Form 10-Q for the three months ended March 31, 2011, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

(Logo:  

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
11. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... -- CVS Health (NYSE: CVS ) announced today ... regional health systems to enhance access to high-quality, affordable health ... Health System in Alabama ; Community Health ... Pennsylvania , Northwest Medical Center, including Oro Valley ... in Tennessee ; and Premier Health in ...
(Date:10/30/2014)...  CytRx Corporation (NASDAQ: CYTR ), ... oncology, today announced an upcoming presentation highlighting its ... The presentation, titled, "Drug Conjugates Bind Covalently to ... Sant P. Chawla , M.D., F.R.A.C.P., Director ... of the Company,s ongoing global, pivotal Phase 3 ...
(Date:10/30/2014)... Oct. 30, 2014 Today, DripDrop, the ... that it was awarded a two-year contract, effective ... company that serves the more than 100,000 members ... Association and Provista.  DripDrop also ... from member hospitals who attended the recent Novation ...
Breaking Medicine Technology:CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 2DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 4
... ,, LAIYANG, China , July 9 /PRNewswire-Asia-FirstCall/ -- ... present at the Global Hunter Securities,China Investment Conference, which takes place July 11-13, 2010 ... , , ... 2010 , , , ...
... July 8 Sysmex, a global leader ... technology, today announced a three-year, dual source urinalysis ... purchasing/leasing access to Sysmex automated urine particle analyzers, ... for Amerinet members will be provided through Sysmex ...
Cached Medicine Technology:Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference 2Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference 3Sysmex America Announces Amerinet Urinalysis Contract 2Sysmex America Announces Amerinet Urinalysis Contract 3
(Date:10/30/2014)... 2014 Horse Sense & Sensitivity ... to special needs individuals in the Jacksonville area, will ... 15 from 10-2:00 p.m. at Bailey's Farm (2202 Bishop ... the public and is designed to raise awareness and ... the HSS Round-Up is free. Ticket purchases will be ...
(Date:10/30/2014)... The annual meeting of The North ... on Saturday, October 18th, marking the end of the ... NAMS is North America’s leading non-profit organization dedicated to ... women during midlife and beyond through an understanding of ... thought leaders from fields as varied as gynecology, sociology, ...
(Date:10/30/2014)... Amy Norton HealthDay ... Exposure to a common plastics, chemical during pregnancy may have ... hints. Researchers found that baby boys born to moms ... have a shorter anogenital distance -- the space between the ... and it,s considered a marker of exposure to androgens ("male" ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- A new ... life-threatening meningococcal disease was approved by the U.S. Food ... to protect people between the ages of 10 and ... meningitidis serogroup B bacteria. The bacteria can ... the spinal cord and brain. It is a leading ...
(Date:10/29/2014)... cancer medications are linked with an increased risk of ... failure or prior heart attacks. Published in BJU ... weigh the benefits and risks of the drugs. ... male hormones in the body to prevent them from ... prostate cancer. Despite its anticancer effects, ADT has been ...
Breaking Medicine News(10 mins):Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Prostate cancer medications linked with increased risk of heart-related deaths in men with cardiovascular problems 2
... released important information about epilepsy and seizure,disorders to dispel ... Edward Kennedy (D-Mass)., Senator Kennedy, 76, one of ... a seizure on Saturday. A seizure is a,disturbance in ... Americans,will have a single seizure at some point in ...
... foods, such as bread, pasta, often goes unnoticed , , ... lead to improved diagnosis and treatment of celiac disease, ... meeting in San Diego. , Celiac disease, which ... an autoimmune disorder in the small intestine triggered by ...
... developing reliable genetic tests to guide lung cancer treatment ... recently evaluated the ability of five high-risk genetic profiles, ... recur in patients whose non-small cell lung cancer was ... findings at the American Thoracic Societys 2008 International Conference ...
... 19 Roche Diagnostics today announced,that Quest Diagnostics ... of,diagnostic testing, information and services, has signed a ... TaqMan(R) HIV-1 Test for,HIV viral load testing., ... effects of,antiretroviral therapy by measuring changes in HIV-1 ...
... Risks and Identifies ... Approaches to Manage Those Risks, SCHAUMBURG, Ill., May 19 ... of gas, inflation is affecting every,American. Among the largest groups affected ... current retirees who are experiencing,soaring costs in a volatile economy., ...
... 19 On May 13, 2008, the Cancer,Prevention Coalition, ... FDA. This updates scientific information detailed in a,November 17, ... It also,documents prior knowledge of the FDA and industry ... basis of the 2008 Petition is detailed in 11 ...
Cached Medicine News:Health News:The Epilepsy Foundation Sheds Light on Seizures 2Health News:Advances Aid Treatment, Diagnosis of Celiac Disease 2Health News:Advances Aid Treatment, Diagnosis of Celiac Disease 3Health News:Will lung cancer recur? A genetic test may provide the answer 2Health News:Quest Diagnostics Chooses Roche's Fully Automated, Real-Time HIV-1 Viral Load Monitoring Test For Its Customers in Laboratories Nationwide 2Health News:Inflation Ranks as Today's Top Retirement Concern 2Health News:Inflation Ranks as Today's Top Retirement Concern 3Health News:Inflation Ranks as Today's Top Retirement Concern 4Health News:Petition Seeking a Cancer Warning on Cosmetic Talc Powder Products 2
IMMCO ANA Elisa meets the guidelines for the laboratory diagnosis and monitoring of systemic autoimmune rheumatic diseases intended for the use of clinical pathologists and laboratory physicians....
An enzyme-linked immuno-sorbent assay for the detectionand quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Jerome Halo Traction Units provide optimum immobilization for unstable injuries of the spine. The Generation 80 superstructure is available with either 2-point (serrated disk), or 3-point (flexion/ex...
... Boston Scoliosis Brace™ for neuromuscular ... a lightweight, soft, and easy ... maximum comfort. The Soft ... of non-cracking orthopedic grade copolymer ...
Medicine Products: